UroGen Pharma's low P/S ratio may reflect market expectation...

Moomoo AI Mar 17, 2024 21:56

UroGen Pharma's low P/S ratio may reflect market expectations of continued poor revenue growth. The company's projected weaker growth than the industry could explain why investors are paying less for the stock.

Revenues Working Against UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Following 25% Dive

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

7713 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4820

Followers

Following

11K

Visitors